Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 6/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25938922 | 1.00 | LTA4H (0.41) | LTA4HCNR1GRM5NTRK1PRMT5 | |
| SCHEMBL25935234 | 0.92 | LTA4H (0.41) | LTA4HCNR1FEN1NR1H4S1PR5 | |
| SCHEMBL25031039 | 0.84 | GRM5 (0.33) | CNR1GRM5FEN1NR1H4S1PR5 | |
| SCHEMBL25938924 | 0.84 | GRM5 (0.33) | CNR1GRM5FEN1NR1H4S1PR5 | |
| SCHEMBL30479056 | 0.84 | GRM5 (0.33) | CNR1GRM5FEN1NR1H4S1PR5 | |
| SCHEMBL25034787 | 0.82 | FFAR4 (0.40) | CNR1GRM5FFAR4 | |
| SCHEMBL30135909 | 0.82 | FFAR4 (0.40) | CNR1GRM5FFAR4 | |
| SCHEMBL25031490 | 0.82 | GRM5 (0.37) | LTA4HCNR1GRM5PRMT5FEN1 | |
| SCHEMBL30479062 | 0.82 | GRM5 (0.37) | LTA4HCNR1GRM5PRMT5FEN1 | |
| SCHEMBL29013187 | 0.77 | GRM5 (0.38) | GRM5FEN1S1PR5PTGDR2FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116261458-B | PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2024-05-24 | — | — | CN | disclosed |
| US-11939334-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-03-26 | — | — | US | disclosed |
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-08-03 | — | — | US | disclosed |
| CN-116261458-A | Novel PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2023-06-13 | — | — | CN | disclosed |
| EP-4157850-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | Uppthera, Inc. (KR) | 2023-04-05 | — | — | EP | disclosed |
| WO-2023017446-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023018236-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939334-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | PLK1, BUB1B, BUB1 | LTA4H 3856/4885CNR1 4344/4885GRM5 1390/4885 |
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | LTA4H 4070/4885CNR1 4569/4885GRM5 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.